Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05724797
Other study ID # NRS-033-102
Secondary ID UG3DA048234
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 17, 2023
Est. completion date June 30, 2024

Study information

Verified date April 2024
Source Nirsum Labs
Contact Nirsum Clinical Operations
Phone 646-849-5601
Email clinicaltrials@nirsum.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age, inclusive.


Description:

Subjects will provide written informed consent and undergo a screening visit within 28 days of receiving study drug. Eligible subjects must have a negative urine drug screen (UDS) and a negative naloxone challenge test at Screening and at the check-in visit (Day -1). Upon completion of screening, eligible subjects will be admitted to the clinical research unit (CRU) on Day -1 and remain confined in the CRU through completion of all scheduled procedures on Day 4 to allow for safety labs, pharmacokinetic (PK) blood draws, ECGs, injection site assessments, and adverse event monitoring. Study medication dosing will occur in the morning on Day 1 and serial blood samples for plasma concentration determination for PK analysis will be taken during this time at pre-dose and 0.25, 0.50, 1, 1.5, 2, 4, 8, 10, 12, 24 (day 2), 48 (day 3), and 72 (day 4) hours post dose. Additional blood PK samples will be taken at follow-up visits. A Safety Review Committee (SRC) will review blinded, preliminary data from Cohort 1 to make recommendations regarding escalation to Cohorts 2 and 3.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Male or female =18 and =55 years of age at time of consent - Body mass index =18.0 to =35.0 kg/m2 - Medically healthy based on the absence of clinically significant abnormal vital sign - Females must have a negative serum pregnancy test at time of screening and negative urine pregnancy test upon admission; also, females of childbearing potential must agree to use a highly effective means of contraception from Screening until 9 months after receiving the study medication. - Male subjects with female partners of childbearing potential must agree to use a male condom and will be advised of the benefit for a female partner to use a highly effective method of contraception - Agree to stay within National Institute on Alcohol Abuse and Alcoholism (NIAAA) low risk drinking criteria. For women, low-risk drinking is no more than 3 drinks on any single day and no more than 7 drinks per week. For men, it is defined as no more than 4 drinks on any single day and no more than 14 drinks per week. - Agree not to take opioid analgesics. Exclusion Criteria: - Clinically significant medical or psychiatric diagnosis (assessed on history, physical exam, ECG, and/or blood tests; includes significant history of cardiovascular, pulmonary, hepatic, gallbladder, or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, or active sexually transmitted disease). - Significant neuropsychiatric diagnosis (e.g., major depression, suicidal ideation, multiple sclerosis, dementia) as reported by the subject, or a past history of suicide attempt. - Females who are pregnant, lactating, or likely to become pregnant during the study. - History over last 30 days of consuming alcohol >3 drinks day per day or >7 drinks per week if female; if male >4 drinks per day or >14 drinks per week. - Currently uses tobacco or nicotine containing products, including but not limited to cigarettes, electronic cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum. - Reported history of a significant traumatic injury, major surgery, or open biopsy within the 4 weeks prior to signing the informed consent form. - Subject reported history of any use of long-term use of opioids agonists or antagonists; e.g., methadone, oxycodone, hydrocodone, naltrexone, buprenorphine. - Subject reported history of any medications to treat opioid use disorder (MOUD); e.g., methadone, naltrexone, buprenorphine, kratom. - Subject reports anticipated need for opioid analgesia in the next 12 months (e.g., planned surgery). - Subject reports history or presence of allergic or adverse response (including rash or anaphylaxis) to naloxone, naltrexone, nalmefene, morphinan opioid agonists, benzyl alcohol or sesame oil. - Positive urine drug screen (UDS) for barbiturates, benzodiazepines, cocaine, methamphetamine, or opioids. - Positive alcohol breath test. - Received an investigational drug within the last 30 days or 5 half-lives of the drug, whichever is longer, prior to administration of study medication. - Has taken exclusionary prohibited medications within the last 30 days or 5 half-lives of the drug, whichever is longer. - Subjects with a history of syncope, or have a history of symptomatic hypotension or symptomatic hypoglycemia. - Subjects who test positive for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbsAg), or Hepatitis C virus (HCV) antibody.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NRS-033
A single dose of NRS-033 will be administered
Placebo
A single dose of matching placebo will be administered

Locations

Country Name City State
United States Frontage Clinical Research Center Secaucus New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Nirsum Labs National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment Emergent Adverse Events (TEAEs) Number of Participants with TEAEs From predose through end of study visit, assessed up to 6 months
Primary Severity of TEAEs Severity of TEAEs From predose through end of study visit, assessed up to 6 months
Primary Serious Adverse Events (SAEs) Number of Participants with SAEs From predose through end of study visit, assessed up to 6 months
Primary Discontinuation Due to Adverse Events (AEs) Number of Participants who discontinue the study due to AEs From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: AUC0-last Area under the plasma concentration-time curve (AUC) from time 0 to last measurable plasma concentration From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: AUC0-infinity Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC0-last + AUCt-inf From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: AUC0-inf %extrapolation Percentage of AUC0-inf due to extrapolation from Tlast to infinity From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: Cmax Maximum observed plasma concentration (Cmax) From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: Tmax Time of Cmax From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: t1/2 Terminal half-life (t1/2) From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: Kel (?z) Apparent terminal rate-constant, calculated using linear regression on the terminal portion of the Log-concentration versus time curve From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: Vz/F Apparent volume of distribution (Vz/F) From predose through end of study visit, assessed up to 6 months
Primary Pharmacokinetics: CL/F Apparent clearance (CL/F) From predose through end of study visit, assessed up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1